20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with dabigatran in 1 studies
| Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) |
|---|---|---|---|---|---|
| 640 | 13 | 233 | 3,887 | 261 | 3,490 |
| Protein | Taxonomy | 20-hydroxy-5,8,11,14-eicosatetraenoic acid (IC50) | dabigatran (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 4.7 | |
| Prothrombin | Homo sapiens (human) | 0.0046 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 8.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bar, A; Chlopicki, S; Enggaard, C; Hansen, PBL; Jasztal, A; Jensen, B; Kieronska-Rudek, A; Kij, A; Marczyk, B; Mateuszuk, L; Matyjaszczyk-Gwarda, K; Proniewski, B; Przyborowski, K; Tworzydlo, A; Walczak, M | 1 |
1 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and dabigatran
| Article | Year |
|---|---|
Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice.
Topics: Angiotensin II; Animals; Antithrombins; Chromatography, Liquid; Dabigatran; Disease Models, Animal; Hydroxyeicosatetraenoic Acids; Hypertension; Intercellular Adhesion Molecule-1; Male; Mice; Nitric Oxide; Tandem Mass Spectrometry; Vascular Remodeling; von Willebrand Factor | 2021 |